🚀 Is #AI the future of drug development? AI #startups are transforming drug development, drastically reducing time and costs. With over €16 billion invested, the potential is undeniable. 🌎 While the USA and UK lead, this global shift promises faster, safer treatments. 🗞️ Read the full article through the link in the comments – thanks, Plattform Life Sciences, for publishing this insightful piece by Dr. Fei Tian and Andreas Kastenbauer. 👏🏼 🔗 Xaira Therapeutics, Genesis Therapeutics, Exscientia, BenevolentAI, Relay Therapeutics, BioXcel Therapeutics, Inc., Biofourmis,
MIG Capital
Wagniskapital- und Private-Equity-Auftraggeber
Together, we build companies that move the world forward.
Info
MIG Capital is one of the leading German early-stage VC investors. We turn vision into value by providing financing to young innovative companies in Life Science and Deep Tech across Europe. Since our beginnings in 2004, we have invested more than €650 million in ~50 companies. Today, our portfolio consists of 30 groundbreaking companies.
- Website
-
http://mig.ag
Externer Link zu MIG Capital
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- München
- Art
- Privatunternehmen
- Gegründet
- 2004
- Spezialgebiete
- Venture capital, Entrepreneurship, Deep tech, Life sciences und Private equity
Orte
-
Primär
Wegbeschreibung
102 Ismaninger Straße
München, 81675, DE
Beschäftigte von MIG Capital
Updates
-
MIG Capital hat dies direkt geteilt
🏭 𝗦𝘂𝗻-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻: 𝗗𝗲𝗰𝗮𝗿𝗯𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗛𝗲𝗮𝘁 𝗳𝗼𝗿 𝗮 𝗚𝗿𝗲𝗲𝗻𝗲𝗿 𝗙𝘂𝘁𝘂𝗿𝗲 ☀ In early July, we proudly announced our investment in GlassPoint, Inc, the leader in solar industrial process heat. In my latest article, I dive into the cutting-edge technologies and innovative strategies that are driving the decarbonization of #IndustrialProcessHeat. Check out why MIG Capital is so excited about this ‘hot’ opportunity and why we chose GlassPoint for our first investment in this space. Read the full article here: https://lnkd.in/gYSD3YR4 Soren Hein Christina Vogt-Sasse Rod MacGregor Markus Balz #CleantTech #DeepTech #RenewableEnergy #Sustainability #Decarbonization #VentureCapital
-
Did you know there’s an International Dog Day? It’s actually 𝘵𝘰𝘥𝘢𝘺: Happy IDD! 🐕 Pets are more than just companions — over half of pet owners say their pet is “as much a part of their family as a human member.” As our pets become more important in our lives, so does their health. 🐾 The result? 🚀 #Startups in animal health are booming, making it an exciting space for venture capital. 👩🏻🔬 From AI-powered diagnostics like our portfolio company HawkCell to other innovative players such as ASTRA Therapeutics, the future of pet care is filled with potential. 👏🏼 We're excited to see the next generation of companies shaping the future of #animalhealth. 🔗 Advanced Animal Diagnostics, PetPace, HerdDogg, Inc., Connecterra, Vetigenics, Armenta, Vetcove, Digitail, INSYLO TECHNOLOGIES, Native Pet, String Bio Private Limited, Calysta
-
-
🎉 Thrilled to be highlighted by Startup Insider as the "VC of the Day"! 🎉 At MIG, we're all about backing innovative #DeepTech and #LifeSciences startups worldwide and supporting our portfolio companies for long-term growth. 𝐇𝐨𝐰? 👩🏻🔬🧑🏽💻Our diverse team, with expertise spanning engineering, medicine, sciences, entrepreneurship, and beyond, enables us to spot opportunities and navigate risks with precision – always with the founders in mind. 🚀 Check out some of our featured investments: IQM Quantum Computers, NavVis, KONUX, AMSilk GmbH | Biotech Materials, Look Up Space, and more.
𝐕𝐂 𝐝𝐞𝐬 𝐓𝐚𝐠𝐞𝐬: 𝐌𝐈𝐆 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 MIG Capital, ein führender Early-Stage Venture Capital-Investor, investiert über die MIG Fonds in vielversprechende DeepTech- und Life Sciences-Unternehmen im deutschsprachigen Europa und darüber hinaus. Das Unternehmen konzentriert sich auf Series A Deals mit einem initialen Investment zwischen 1 und 10 Millionen Euro, wobei der Sweet Spot bei 3 bis 5 Millionen Euro liegt. 𝐄𝐫𝐟𝐚𝐡𝐫𝐭 𝐦𝐞𝐡𝐫 ü𝐛𝐞𝐫 𝐌𝐈𝐆 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐢𝐧 𝐮𝐧𝐬𝐞𝐫𝐞𝐧 𝐤𝐨𝐬𝐭𝐞𝐧𝐥𝐨𝐬𝐞𝐧 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐞𝐧 𝐑𝐞𝐩𝐨𝐫𝐭 - 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝-𝐋𝐢𝐧𝐤 𝐢𝐧 𝐝𝐞𝐧 𝐊𝐨𝐦𝐦𝐞𝐧𝐭𝐚𝐫𝐞𝐧! 𝐁𝐞𝐬𝐨𝐧𝐝𝐞𝐫𝐡𝐞𝐢𝐭𝐞𝐧 𝐯𝐨𝐧 𝐌𝐈𝐆 𝐂𝐚𝐩𝐢𝐭𝐚𝐥: - Seit der Gründung hat MIG Capital über 730 Millionen Euro in mehr als 50 Unternehmen investiert, die in Bereichen wie Biopharma, Energie- und Umwelttechnologien, Advanced Computing, Digitalisierung/IoT, New Materials, MedTech und Digital Health tätig sind. - Das Investment Team von MIG Capital, das über vielfältige Hintergründe in Ingenieurswissenschaften, #Medizin, Biologie, Physik, Jura und Unternehmertum verfügt, bewertet Risiken und Chancen von Geschäftsmodellen und Technologien mit analytischer Präzision und kreativen Prozessen. Diese Expertise und das breite Netzwerk des Teams ermöglichen es MIG Capital, das Wachstum seiner Portfoliounternehmen nachhaltig zu fördern. 𝐁𝐞𝐤𝐚𝐧𝐧𝐭𝐞 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: BioNTech SE (exited), IQM Quantum Computers, NavVis, KONUX, AMSilk GmbH | Biotech Materials, APK AG 𝐓𝐞𝐚𝐦: u.a. Michael Motschmann, Maria B., Kristian Schmidt-Garve, Andreas Kastenbauer, Dr. Fei Tian, Jürgen Kosch, Paulina Bzowa, Frederick Michna, Christina Vogt-Sasse, Soren Hein, Montana Nick, Matthias Kromayer, Cecilia Pontini, Boris Bernstein, Matthias Guth, Anna Wiedemann, Barbara Steingruber-Dotterweich, Oliver Kahl, Gero Fiedler, Laura P. #𝐌𝐈𝐆 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 #𝐈𝐍𝐕𝐄𝐒𝐓𝐎𝐑𝐄𝐍𝐑𝐄𝐏𝐎𝐑𝐓 #𝐒𝐓𝐀𝐑𝐓𝐔𝐏𝐈𝐍𝐒𝐈𝐃𝐄𝐑
-
-
Excited to see talpasolutions and KONUX recognized in the 7th edition of the German AI Startup Landscape by appliedAI Institute for Europe gGmbH! 🚀 🔗 Check out their report: https://lnkd.in/dH5x5xe2
Veröffentlichung der 7. deutschen KI Startup Landscape 🚀 Das appliedAI Institute for Europe gGmbH präsentiert die 7. Ausgabe der deutschen KI-Startup Landscape, die umfassendste Analyse des deutschen KI-Startup-Ökosystems. Sei morgen um 15 Uhr dabei und erfahre aus erster Hand die Ergebnisse der Analyse in unserer Zoom-Session. Nehme teil und nutze die Chance direkt, um Fragen zu stellen: https://lnkd.in/dJR_2fFM. Highlights der Analyse: 🔍 Umfassende Analyse: Eine detaillierte Analyse über die deutsche KI-Startup-Szene. 🔒 Validierte Startups: Hochwertige, von Experti:innen validierte KI-Startups. 🤝 Ecosystem Building: Förderung der Zusammenarbeit zwischen Startups, Unternehmen und Regierung. Erfahre hier mehr über die KI-Startup-Szene in Deutschland auf unserer Website https://lnkd.in/dH5x5xe2. Ein herzliches Dankeschön geht an unsere Kontributoren, die die Entstehung dieser Analyse ermöglicht haben: Deutsche Telekom, NVIDIA, Intel Corporation, UnternehmerTUM, Cherry Ventures, Earlybird Venture Capital, UVC Partners, Yttrium, HTGF | High-Tech Gründerfonds, eCAPITAL ENTREPRENEURIAL PARTNERS, Burda Principal Investments, HV Capital, D11Z. Ventures GmbH & Co. KG, MIG Capital und AI.FUND. #AI #Startups #Innovation #Deutschland #KI Dr. Frauke Goll I Dr. Philip Hutchinson
-
-
🧬 The FDA database now has over 800 approved applications of #AI in medical technology – what a boom! 🧬 AI startups like Augmedix and CloudMedx are leading innovations in radiology, oncology, and cardiology, with major players like Microsoft and Google also getting involved. 🏥 Check out our latest blog post where Dr. Fei Tian discusses the rise of AI-driven #MedTech startups transforming patient care! 👏🏼 We see this change as a great opportunity for investors, healthcare professionals, and, of course, patients.
-
inbolt is featured in the cover story of Venture Capital Journal! 🌟 🦾 Their AI software is transforming robots with #3D vision, allowing them to work more like humans in complex environments. “We bring vision to the robot, so we bring in eyes and the brain,” says Inbolt's co-founder and CEO Rudy Cohen. TUM Venture Labs Albane Dersy Oliver Kahl SOSV #VCJ #Robotics #AI #VentureCapital
-
-
So proud of Albane Dersy, co-founder and COO at inbolt, for her work and impact. 🚀 🎙️ Check out this insightful discussion on the latest podcast episode with Universal Robots. Albane brilliantly explains how #AI, #vision, and #robotics are revolutionizing automation in unstructured production environments. 🦾
Automation has been difficult (impossible) in "unstructured" production environments. But thanks to AI, vision, and robotics - that has changed 🦾 Albane Dersy from inbolt explains it perfectly here with the example of a fictional cup-picking-process 😂 Do you want more? You can watch the whole interview on YouTube: https://lnkd.in/dK9Qu6at ..or listen to it as a podcast: Apple: https://lnkd.in/e_3fk9G7 Spotify: https://lnkd.in/ehQ8PyhC #automation #ai #manufacturing #robotics #podcast
-
📣 NEW INVESTMENT 📣 We're so excited to announce that MIG Capital co-leads a €63 million Series A round in SciRhom to accelerate iRhom2-targeting therapies in a wide range of autoimmune diseases! 👩🏽⚕️ 𝐖𝐡𝐲 𝐰𝐞 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭: 🧪 𝐓𝐨𝐩-𝐧𝐨𝐭𝐜𝐡 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 SciRhom aims to revolutionize autoimmune disease treatment by targeting iRhom2, a key regulator in disease-related signaling pathways. 🩵 𝐇𝐢𝐠𝐡 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭 iRhom2's transformative potential offers hope for patients with currently difficult-to-treat autoimmune diseases. 👩🏽🤝👨🏼 𝐄𝐱𝐩𝐞𝐫𝐭 𝐭𝐞𝐚𝐦 SciRhom is led by an ambitious and dedicated team with extensive experience in pharma, biotech R&D, and clinical development. 💸 𝐒𝐭𝐫𝐨𝐧𝐠 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐛𝐚𝐜𝐤𝐢𝐧𝐠 The oversubscribed round, co-led by MIG Capital and an international syndicate including Andera Partners, Kurma Partners, Hadean Ventures, and Wellington Partners, joint by other new and existing investors including Bayern Kapital, HTGF | High-Tech Gründerfond, and PhiFund Ventures, demonstrates strong confidence in SciRhom's vision. Dr. Fei Tian, Principal at MIG Capital, comments: “SciRhom's impressive team and innovative approach align with our goal to support disruptive companies with high value and impact. Joining international life science investors in this oversubscribed round bolsters support for SciRhom's novel iRhom2-targeting antibodies as they move into clinical development.” Our entire team is looking forward to the time ahead with SciRhom! 👏🏼 Jens Ruhe Jan Poth Matthias Schneider MIG Fonds Matthias Kromayer
-
-
🔍 Insights from Matthias Kromayer at BayOConnect in Munich! 🔍 This week, Matthias Kromayer held a presentation at BayOConnect by BioM Biotech Cluster Development GmbH. Under the theme "Reflections on AI from an Agnostic VC Investor," Matthias shared MIG Capital’s reflections on the potential impact of #AI within the #biopharma value chain. Key points included: 🚀 The Fight: Understanding the role of AI in revolutionizing clinical trials. 📊 Analysis: Breaking down AI’s potential in enhancing trial design, site selection, real-time monitoring, and patient experiences. 🔍 Conclusion: Assessing AI’s transformative power across the biopharma value chain, from early development to market approval. #BayOConnect2024 was fun – see you next year! 💡 Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie | Roche Deutschland
-